Immuneering (NASDAQ:IMRX) Given Buy Rating at Needham & Company LLC

Needham & Company LLC restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research report released on Tuesday morning,Benzinga reports. The firm currently has a $15.00 target price on the stock.

Several other equities analysts have also issued reports on IMRX. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research note on Friday, December 13th. Chardan Capital restated a “buy” rating and issued a $13.00 price objective on shares of Immuneering in a report on Wednesday, November 20th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating and four have given a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $12.80.

Immuneering Price Performance

Shares of NASDAQ IMRX opened at $2.36 on Tuesday. The business’s 50 day moving average is $2.04 and its two-hundred day moving average is $1.77. Immuneering has a 52-week low of $1.00 and a 52-week high of $7.68. The firm has a market cap of $73.28 million, a price-to-earnings ratio of -1.20 and a beta of -0.34.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Acadian Asset Management LLC acquired a new stake in shares of Immuneering in the 2nd quarter valued at $67,000. Renaissance Technologies LLC purchased a new position in Immuneering in the second quarter valued at $447,000. XTX Topco Ltd raised its stake in Immuneering by 37.3% in the second quarter. XTX Topco Ltd now owns 34,159 shares of the company’s stock valued at $44,000 after buying an additional 9,274 shares in the last quarter. Marshall Wace LLP purchased a new stake in Immuneering during the 2nd quarter worth about $492,000. Finally, Point72 Asia Singapore Pte. Ltd. acquired a new position in shares of Immuneering during the 2nd quarter worth about $44,000. Hedge funds and other institutional investors own 67.65% of the company’s stock.

Immuneering Company Profile

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.